Helixmith Co., Ltd

KOSDAQ 084990.KQ

Helixmith Co., Ltd Return on Capital Employed (ROCE) for the year ending December 31, 2023: -40.92%

Helixmith Co., Ltd Return on Capital Employed (ROCE) is -40.92% for the year ending December 31, 2023, a -120.78% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Helixmith Co., Ltd Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -18.53%, a 26.14% change year over year.
Helixmith Co., Ltd Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -25.09%, a -39.06% change year over year.
Helixmith Co., Ltd Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -18.04%, a 41.78% change year over year.
Helixmith Co., Ltd Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -30.99%, a -161.32% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

KOSDAQ: 084990.KQ

Helixmith Co., Ltd

CEO	Mr. Sunyoung Kim D.Phil., Ph.D.
IPO Date	Dec. 29, 2005
Location	South Korea
Headquarters	Building 203
Employees	132
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological diseases. The company's pipeline products include VM206, a therapeutic cancer vaccine targeting HER2/neu positive breast or ovarian cancer; and VM501, a re-engineered form of interleukin 11 targeting chemotherapy-induced thrombocytopenia. Its clinical trials biologics comprise VM202-DPN, VM202-PAD, VM501, VM202-ALS, VM202-CAD, and VM206. The company was formerly known as ViroMed Co., Ltd. and changed its name to Helixmith Co., Ltd in April 2019. Helixmith Co., Ltd was incorporated in 1996 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years